Doctoral student Sidi Bencherif will present this research, Sunday, Aug. 17 at the 236th national meeting of the American Chemical Society in Philadelphia.

Currently, physicians are able to treat patients with damaged bone tissue, like those who have bone fractures that fail to heal, using demineralized bone matrix, a biological material obtained from cadavers. Demineralized bone matrix is rich in growth factor proteins which signal bone cells in the area to multiply and form complex bone tissue, while other proteins in the matrix regulate the activity of the growth factors. Demineralized bone matrix is in limited supply, and because it comes from a human donor, there is a risk of transmitting viruses to the recipient.

"Tissue engineering is an exciting field. We're creating solutions to problems that can significantly impact people's quality of life," said Washburn, an assistant professor of chemistry and biomedical engineering at Carnegie Mellon. "These gels have great promise in not only regenerating bone, but serving as a gene therapy delivery system."

Members of the Washburn lab have been developing synthetic alternatives to demineralized bone matrix. In the work being presented today, they created a flexible hydrogel using biologically active and degradable hyaluronic acid. Hydrogels, which are considered to be the state-of-the-art in tissue design, are made from polymers that swell in water to form a gel-like material. They interact with growth factors much like demineralized bone matrix does, providing scaffolding for bone cells to proliferate and form new tissue. The researchers found that, in vitro, the hydrogels promoted cell proliferation, differentiation and mineralization of pre-osteoblast cells.

Further research by the group has created a hybrid hydrogel that incorporates a nanogel structure. This new hydrogel promotes the differentiation of cells, much like the hyaluronic acid gel while also releasing nanogels in a controlled and targeted manner. The researchers hope that this structure could be used to partner tissue engineering with gene therapy.

This work was funded by the National Tissue Engineering Center, the National Institutes of Health and a 3M Non-Tenured Faculty grant.

Note: If no author is given, the source is cited instead.

• Osteoporosis
• Bone and Spine
• Leukemia

• Biochemistry
• Medical Technology
• Microarrays

• Cartilage
• Bone
• Healing
• Bone fracture
• Bone age
• Tissue engineering